Correspondence 0001493152-23-005155 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: Feb. 15, 2023 · CIK: 0001859007 · Accession: 0001493152-23-005155

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269442

Date

Feb. 15, 2023

Author

Form

CORRESP

Company

ZyVersa Therapeutics, Inc.

Letter

February 15, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, N.E.

Washington, D.C. 20549

Attn: Lauren Hamill

Laura Crotty

Re: ZyVersa Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-269442

Ladies and Gentlemen:

ZyVersa Therapeutics, Inc. hereby requests that its acceleration request dated February 13, 2023 be withdrawn. Please call Jared Kelly of Lowenstein Sandler LLP at (973) 597-2400 with any questions.

Sincerely,
ZYVERSA THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

February
15, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attn:
    Lauren
        Hamill

    Laura
    Crotty

    Re:
    ZyVersa
    Therapeutics, Inc.

    Registration
    Statement on Form S-1, as amended

    File
    No. 333-269442

Ladies
and Gentlemen:

ZyVersa
Therapeutics, Inc. hereby requests that its acceleration request dated February 13, 2023 be withdrawn. Please call Jared Kelly of Lowenstein
Sandler LLP at (973) 597-2400 with any questions.

    Sincerely,

    ZYVERSA THERAPEUTICS INC.

    By:
    /s/
    Stephen Glover

    Name:
    Stephen Glover

    Title:
    Chief Executive Officer

SecProbe.io